StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)

Close on Nov 17, 2026Market cap $15.86BP/E –Yield –

Charles River Laboratories International total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Charles River Laboratories International's total debt was $2.63B at Jun 27, 2026. For fiscal 2025 it was $2.14B, down 4.6% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $2.71B in fiscal 2022.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 27, 2025$2.14B-4.6%
FY2024Dec 28, 2024$2.24B-15.5%
FY2023Dec 30, 2023$2.65B-2.2%
FY2022Dec 31, 2022$2.71B+1.7%
FY2021Dec 25, 2021$2.66B+34.7%
FY2020Dec 26, 2020$1.98B+4.9%
FY2019Dec 28, 2019$1.89B+13.2%
FY2018Dec 29, 2018$1.66B+48.6%
FY2017Dec 30, 2017$1.12B-7.6%
FY2016Dec 31, 2016$1.21B+45.0%
FY2015Dec 26, 2015$836.23M+10.9%
FY2014Dec 27, 2014$753.75M+13.7%
FY2013Dec 28, 2013$663.05M-0.5%
FY2012Dec 29, 2012$666.45M-7.2%
FY2011Dec 31, 2011$717.90M+2.4%
FY2010Dec 25, 2010$700.75M+42.2%
FY2009Dec 26, 2009$492.83M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$2.63B+12.6%
Q1 FY2026Mar 28, 2026$2.67B+6.3%
Q4 FY2025Dec 27, 2025$2.14B-4.6%
Q3 FY2025Sep 27, 2025$2.19B-6.1%
Q2 FY2025Jun 28, 2025$2.33B-3.2%
Q1 FY2025Mar 29, 2025$2.51B-5.6%
Q4 FY2024Dec 28, 2024$2.24B-15.5%
Q3 FY2024Sep 28, 2024$2.33B-7.5%
Q2 FY2024Jun 29, 2024$2.41B-10.1%
Q1 FY2024Mar 30, 2024$2.66B-3.2%
Q4 FY2023Dec 30, 2023$2.65B-2.2%
Q3 FY2023Sep 30, 2023$2.52B-14.4%
Q2 FY2023Jul 1, 2023$2.68B-10.6%
Q1 FY2023Apr 1, 2023$2.75B+2.7%
Q4 FY2022Dec 31, 2022$2.71B+1.7%
Q3 FY2022Sep 24, 2022$2.94B+1.5%
Q2 FY2022Jun 25, 2022$3.00B+9.9%
Q1 FY2022Mar 26, 2022$2.68B+21.5%
Q4 FY2021Dec 25, 2021$2.66B+34.7%
Q3 FY2021Sep 25, 2021$2.89B+43.7%
Q2 FY2021Jun 26, 2021$2.73B+20.8%
Q1 FY2021Mar 27, 2021$2.20B-7.1%
Q4 FY2020Dec 26, 2020$1.98B+4.9%
Q3 FY2020Sep 26, 2020$2.01B+5.2%
Q2 FY2020Jun 27, 2020$2.26B+9.0%
Q1 FY2020Mar 28, 2020$2.37B+51.1%
Q4 FY2019Dec 28, 2019$1.89B+13.2%
Q3 FY2019Sep 28, 2019$1.91B+14.5%
Q2 FY2019Jun 29, 2019$2.07B+14.1%
Q1 FY2019Mar 30, 2019$1.57B+41.4%
Q4 FY2018Dec 29, 2018$1.66B+48.6%
Q3 FY2018Sep 29, 2018$1.67B+44.2%
Q2 FY2018Jun 30, 2018$1.82B+62.1%
Q1 FY2018Mar 31, 2018$1.11B-5.5%
Q4 FY2017Dec 30, 2017$1.12B-7.6%
Q3 FY2017Sep 30, 2017$1.16B-6.5%
Q2 FY2017Jul 1, 2017$1.12B–
Q1 FY2017Apr 1, 2017$1.17B–
Q4 FY2016Dec 31, 2016$1.21B–
Q3 FY2016Sep 24, 2016$1.24B–

More Charles River Laboratories International figures

See a number that looks wrong?